The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies

BACKGROUND: There are currently no FDA-approved biological or chemical drugs for the treatment of HBV-related liver fibrosis or cirrhosis. Some Chinese patent medicines have proven to be effective in this area. OBJECTIVE: The network meta-analysis (NMA) is to evaluate whether entecavir combined with...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yudi, Zhao, Junkai, Wang, Sudan, Huang, Haoming, Hong, Junwei, Zuo, Junling, Huo, Shaochuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/
https://www.ncbi.nlm.nih.gov/pubmed/31145288
http://dx.doi.org/10.1097/MD.0000000000015732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/
https://www.ncbi.nlm.nih.gov/pubmed/31145288
http://dx.doi.org/10.1097/MD.0000000000015732

Ejemplares similares